Mesecar < FHD 2024 >

His work includes developing non-covalent, selective inhibitors designed to work against multiple emerging coronavirus strains, including MERS-CoV.

He is the Robert Wallace Miller Director of the Purdue Institute for Cancer Research , where he leads efforts in developing novel cancer therapies, diagnostics, and targeting cancer at the cellular level. mesecar

Dr. Mesecar's team played a crucial role in identifying the antiviral X77 , which was effective against the SARS-CoV-2 main protease ( Mprocap M raised to the p r o power His work includes developing non-covalent

), helping guide the development of treatments like . mesecar